Literature DB >> 18483877

Somatostatin in medium-sized aspiny interneurons of striatum is responsible for their preservation in quinolinic acid and N-methyl-D-asparate-induced neurotoxicity.

Ujendra Kumar1.   

Abstract

Somatostatin (SST) is a multifunctional peptide and involves in several neurodegenerative diseases. N-Methyl-D-asparate (NMDA) receptor agonist quinolinic acid (QUIN)-induced neurotoxicity mimics an experimental model of Huntington's disease that is characterized by the selective preservation of medium-sized aspiny interneurons and degeneration of medium-sized spiny projection neurons in striatum. In QUIN- and NMDA-induced neurotoxicity, increased expression of SST and messenger RNA levels along with SST release in culture medium is generally observed. However, the molecular mechanisms and the functional consequences of increased SST are still obscure. In the present study, the role of SST was determined using immunoneutralization and immunoblockade of SST in cultured striatal neurons upon QUIN- and NMDA-induced neurotoxicity. The immunoblockade of SST with antisense oligonucleotides and immunoabsorption of released SST with specific antibodies potentiate QUIN- and NMDA-induced neuronal cell death. NADPH-diaphorase positive neurons that are selectively spared in several processes of neurodegeneration result in severe damage upon immunoblockade or immunoabsorption of SST. In addition, exogenous SST along with QUIN and NMDA provides selective preservation of projection neurons, which are selectively susceptible in excitotoxicity. Neuroprotective effect of SST is completely blocked by pertussis toxins, suggesting the role of somatostatin receptors. Taken together, these results provide first evidence that the presence of SST is a unique feature for the selective sparing of medium sized aspiny interneurons in excitotoxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18483877     DOI: 10.1007/s12031-008-9093-3

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  48 in total

1.  Neurons containing NADPH-diaphorase are selectively resistant to quinolinate toxicity.

Authors:  J Y Koh; S Peters; D W Choi
Journal:  Science       Date:  1986-10-03       Impact factor: 47.728

2.  Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation.

Authors:  Takashi Saito; Nobuhisa Iwata; Satoshi Tsubuki; Yoshie Takaki; Jiro Takano; Shu-Ming Huang; Takahiro Suemoto; Makoto Higuchi; Takaomi C Saido
Journal:  Nat Med       Date:  2005-03-20       Impact factor: 53.440

3.  Expression of NMDA receptor-1 (NR1) and huntingtin in striatal neurons which colocalize somatostatin, neuropeptide Y, and NADPH diaphorase: a double-label histochemical and immunohistochemical study.

Authors:  U Kumar; K Asotra; S C Patel; Y C Patel
Journal:  Exp Neurol       Date:  1997-06       Impact factor: 5.330

4.  Anti-somatostatin antibody enhances the rate of hippocampal kindling in rats.

Authors:  A Monno; M Rizzi; R Samanin; A Vezzani
Journal:  Brain Res       Date:  1993-01-29       Impact factor: 3.252

5.  Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease.

Authors:  M F Beal; M F Mazurek; V T Tran; G Chattha; E D Bird; J B Martin
Journal:  Science       Date:  1985-07-19       Impact factor: 47.728

6.  Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease.

Authors:  D Dawbarn; M E De Quidt; P C Emson
Journal:  Brain Res       Date:  1985-08-12       Impact factor: 3.252

7.  Glutamate receptor-induced 45Ca2+ accumulation in cortical cell culture correlates with subsequent neuronal degeneration.

Authors:  D M Hartley; M C Kurth; L Bjerkness; J H Weiss; D W Choi
Journal:  J Neurosci       Date:  1993-05       Impact factor: 6.167

8.  Regional Neuropeptide Pathology in Alzheimer's Disease: Corticotropin-Releasing Factor and Somatostatin.

Authors:  Garth Bissette; Larry Cook; Wayne Smith; Kenneth C. Dole; Barbara Crain; Charles B. Nemeroff
Journal:  J Alzheimers Dis       Date:  1998-12       Impact factor: 4.472

9.  Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum of Huntington's disease.

Authors:  P J Norris; H J Waldvogel; R L Faull; D R Love; P C Emson
Journal:  Neuroscience       Date:  1996-06       Impact factor: 3.590

10.  A peptidase-resistant cyclic octapeptide analogue of somatostatin (SMS 201-995) modulates seizures induced by quinolinic and kainic acids differently in the rat hippocampus.

Authors:  A Vezzani; R Serafini; M A Stasi; G Viganò; M Rizzi; R Samanin
Journal:  Neuropharmacology       Date:  1991-04       Impact factor: 5.250

View more
  5 in total

1.  Colocalization of somatostatin receptors with DARPP-32 in cortex and striatum of rat brain.

Authors:  Padmesh S Rajput; Geetanjali Kharmate; Ujendra Kumar
Journal:  J Mol Neurosci       Date:  2011-11-25       Impact factor: 3.444

2.  Striatal GABAergic interneuron dysfunction in the Q175 mouse model of Huntington's disease.

Authors:  Sandra M Holley; Laurie Galvan; Talia Kamdjou; Carlos Cepeda; Michael S Levine
Journal:  Eur J Neurosci       Date:  2018-12-10       Impact factor: 3.386

3.  The role of the neuropeptide somatostatin on methamphetamine and glutamate-induced neurotoxicity in the striatum of mice.

Authors:  Lauriaselle Afanador; Ina Mexhitaj; Carolyn Diaz; Dalila Ordonez; Lisa Baker; Jesus A Angulo
Journal:  Brain Res       Date:  2013-03-19       Impact factor: 3.252

4.  Somatostatin receptor 1 and 5 double knockout mice mimic neurochemical changes of Huntington's disease transgenic mice.

Authors:  Padmesh S Rajput; Geetanjali Kharmate; Michael Norman; Shi-He Liu; Bhagavatula R Sastry; Charles F Brunicardi; Ujendra Kumar
Journal:  PLoS One       Date:  2011-09-02       Impact factor: 3.240

5.  Cerebrospinal Fluid Neurofilament Light Chain Is Associated with Kynurenine Pathway Metabolite Changes in Multiple Sclerosis.

Authors:  Cecilia Rajda; Zsolt Galla; Helga Polyák; Zoltán Maróti; Kristóf Babarczy; Dániel Pukoli; László Vécsei
Journal:  Int J Mol Sci       Date:  2020-04-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.